Literature DB >> 30554180

Impact of cerebral blood flow changes due to arterial bypass surgery on cognitive function in adult patients with symptomatic ischemic moyamoya disease.

Wataru Yanagihara1,2, Kohei Chida1,2, Masakazu Kobayashi1,2, Yoshitaka Kubo1, Kenji Yoshida1, Kazunori Terasaki2, Kuniaki Ogasawara1,2.   

Abstract

OBJECTIVE: Some adult patients with moyamoya disease (MMD) undergoing revascularization surgery show an improvement or decline in cognition postoperatively. Revascularization surgery for ischemic MMD augments cerebral blood flow (CBF) and improves cerebral oxygen metabolism. However, cerebral hyperperfusion, which is a short-term, major increase in ipsilateral CBF that is much greater than the metabolic needs of the brain, sometimes occurs as a complication. Cerebral hyperperfusion produces widespread, minimal injury to the ipsilateral white matter and cortical regions. The aim of the present prospective study was to determine how changes in CBF due to arterial bypass surgery affect cognitive function in adult patients with symptomatic ischemic MMD and misery perfusion.
METHODS: Thirty-two patients with cerebral misery perfusion, as determined on the basis of 15O gas positron emission tomography, underwent single superficial temporal artery-middle cerebral artery (M4 in the precentral region) anastomosis. Brain perfusion single-photon emission computed tomography (SPECT) studies were performed preoperatively, on the 1st postoperative day, and 2 months after surgery. Neuropsychological tests were also performed preoperatively and 2 months after surgery.
RESULTS: Postoperative neuropsychological assessments demonstrated cognitive improvement in 10 cases (31%), no change in 8 cases (25%), and decline in 14 cases (44%). Based on brain perfusion SPECT and symptoms, 10 patients were considered to have cerebral hyperperfusion syndrome, and all of these patients exhibited a postoperative decline in cognition. Relative precentral CBF on the 1st postoperative day was significantly greater in patients with postoperative cognitive decline (167.3% ± 15.3%) than in those with improved (105.3% ± 18.2%; p < 0.0001) or unchanged (131.4% ± 32.1%; p = 0.0029) cognition. The difference between relative precentral CBF 2 months after surgery and that before surgery was significantly greater in patients with postoperative cognitive improvement (17.2% ± 3.8%) than in those with no postoperative change (10.1% ± 2.4%; p = 0.0003) or with postoperative decline (11.5% ± 3.2%; p = 0.0009) in cognition.
CONCLUSIONS: Cerebral hyperperfusion in the acute stage after arterial bypass surgery impairs cognitive function. An increase in CBF in the chronic stage without acute-stage cerebral hyperperfusion improves cognitive function in adult patients with symptomatic ischemic MMD and misery perfusion.

Entities:  

Keywords:  123I-IMP = N-isopropyl-p-[123I]-iodoamphetamine; CBF = cerebral blood flow; IQ = intelligence quotient; MCA = middle cerebral artery; MMD = moyamoya disease; OEF = oxygen extraction fraction; PET = positron emission tomography; POD 1 = postoperative day 1; RCBFafMCA = relative CBF in the affected MCA ROI; ROC = receiver operating characteristic; ROI = region of interest; SPECT = single-photon emission computed tomography; STA = superficial temporal artery; WAIS-R = Wechsler Adult Intelligence Scale–Revised; arterial bypass surgery; cerebral hemodynamics; cerebral hyperperfusion syndrome; cognition; moyamoya disease; vascular disorders

Mesh:

Year:  2018        PMID: 30554180     DOI: 10.3171/2018.7.JNS18149

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Optimal timing for measuring cerebral blood flow after acetazolamide administration to detect preexisting cerebral hemodynamics and metabolism in patients with bilateral major cerebral artery steno-occlusive diseases: 15O positron emission tomography studies.

Authors:  Masakazu Kobayashi; Suguru Igarashi; Tatsuhiko Takahashi; Shunrou Fujiwara; Kohei Chida; Kazunori Terasaki; Yoshitaka Kubo; Kuniaki Ogasawara
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

2.  Angiographic Characteristics of Cerebral Perfusion and Hemodynamics of the Bridging Artery After Surgical Treatment of Unilateral Moyamoya Disease.

Authors:  Kun Zhang; Wei Ren; Yu-Xue Sun; Xin-Jun Wang; Chao-Yue Li; Zi-Liang Wang; Tian-Xiao Li; Bu-Lang Gao
Journal:  Front Neurosci       Date:  2022-06-14       Impact factor: 5.152

3.  Preservation of spatial memory and neuroprotection by the fatty acid amide hydrolase inhibitor URB597 in a rat model of vascular dementia.

Authors:  Da-Peng Wang; Qi Lin; Kai Kang; Yi-Fang Wu; Shao-Hua Su; Jian Hai
Journal:  Ann Transl Med       Date:  2021-02

4.  Long-Term Cognitive Changes after Revascularization Surgery in Adult Patients with Ischemic Moyamoya Disease.

Authors:  Shun Uchida; Yoshitaka Kubo; Daisuke Oomori; Masahiro Yabuki; Kei Kitakami; Shunrou Fujiwara; Kenji Yoshida; Masakazu Kobayashi; Kazunori Terasaki; Kuniaki Ogasawara
Journal:  Cerebrovasc Dis Extra       Date:  2021-11-22

5.  Moyamoya disease: A human model for chronic hypoperfusion and intervention in Alzheimer's disease.

Authors:  Xiang Zou; Yifan Yuan; Yujun Liao; Conglin Jiang; Fan Zhao; Ding Ding; Yuxiang Gu; Liang Chen; Ying-Hua Chu; Yi-Cheng Hsu; Patrick Alexander Liebig; Bin Xu; Ying Mao
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-06

6.  Decreased frontal white-matter diffusion and improved cognitive flexibility after burr-hole surgery in moyamoya angiopathy.

Authors:  Lionel Calviere; Paul Loubiere; Melanie Planton; Vanessa Cazzola; Isabelle Catalaa; Helene Mirabel; Jean Christophe Sol; Fabrice Bonneville
Journal:  BMC Neurol       Date:  2020-01-20       Impact factor: 2.474

Review 7.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.